Ertugliflozin for chronic heart failure with added urine testing
Treatments studied
Part of Heart & circulation clinical trials.
This Phase 2 trial studies whether the medication ertugliflozin can help people with chronic heart failure. You would be asked to follow a set treatment plan and complete repeated urine (and other) testing to see how your body responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of chronic heart failure (either systolic or diastolic)
- You take a daily “loop” water pill by mouth (like furosemide) every day
- Your kidney function is enough for the study (eGFR is at least 20)
- You speak English and can follow study procedures
- You can sign informed consent and agree to the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
This study tests if changing how much salt you eat affects how the drug ertugliflozin works in people with type 2 diabetes. You would take either the drug or a placebo (a dummy pill) for a short time while following a low- or high-salt diet, to see how your kidneys and blood vessels respond.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.